Abstract Number: 588 • 2014 ACR/ARHP Annual Meeting
Blacks with As Have Greater Disease Severity Than Whites
Background/Purpose : To compare clinical parameters in African American (AA) patients with ankylosing spondylitis (AS) to white patients. Methods: 539 AS patients (47 B, 492…Abstract Number: 318 • 2014 ACR/ARHP Annual Meeting
HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Background/Purpose: HLA-B27 has a high degree of genetic polymorphism, with more than 105 known subtypes. Enthesitis Related Arthritis (ERA) is most common form of Juvenile Idiopathic Arthritis…Abstract Number: 2617 • 2014 ACR/ARHP Annual Meeting
No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study
Background/Purpose: Chronic inflammatory arthritis is associated with increased cardiovascular disease (CVD) risk. The mechanisms behind this link include chronic inflammation, comorbidities and disease-related drugs. CV…Abstract Number: 2553 • 2014 ACR/ARHP Annual Meeting
Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study
Background/Purpose Patients with ankylosing spondylitis (AS) have high fracture risk. BMD, bone microarchitecture and strength determine fracture risk. However, in AS, DXA-based BMD measurements of…Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…Abstract Number: 587 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of Nonradiographic Axial Spondyloarthritis in Korea: A Comparison with Ankylosing Spondylitis
Background/Purpose: To evaluate the clinical characteristics and outcomes of nonradiographic axial spondyloarthritis (nr-axSpA) in Korean patients. Methods: A retrospective analysis evaluated 155 patients with nr-axSpA…Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…Abstract Number: 2594 • 2014 ACR/ARHP Annual Meeting
Differences in Localization and Activity of the Entheseal Involvement Between Non-Radiographic and Radiographic Axial Spondyloarthritis By the Ultrasound Assessment
Background/Purpose Inflammatory involvement of peripheral enthesis belongs to an important sign of spondyloarthritis (SpA). It may occur in patients with long-term as well as newly…Abstract Number: 2512 • 2014 ACR/ARHP Annual Meeting
Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
Golimumab therapy retention rates in patients with rheumatoid arthritis and seronegative spondyloarthritis: data from the Italian LORHEN registry Background/Purpose The efficacy of Golimumab (GLM) treatment…Abstract Number: 819 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Background/Purpose A phase 2, proof-of-concept study indicated that secukinumab, an anti–IL-17A monoclonal antibody, suppressed signs and symptoms of active ankylosing spondylitis (AS) by Week (Wk)…Abstract Number: 583 • 2014 ACR/ARHP Annual Meeting
What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
Background/Purpose Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease…Abstract Number: 246 • 2014 ACR/ARHP Annual Meeting
Neuropathic PAIN in Patients with Ankylosing Spondylitis
Background/Purpose: There is only one study in the literature indicating that neuropathic pain occurs in ankylosing spondylitis (AS) (1). Methods: The aim of this cross…Abstract Number: 2613 • 2014 ACR/ARHP Annual Meeting
Positive Spine MRI for Inflammation Predicts Radiographic Progression in Patients with Ankylosing Spondylitis
Background/Purpose: Inflammation at vertebral corners on MRI has been shown to predict development of syndesmophytes in patients with AS. However, it is unclear at a…Abstract Number: 2303 • 2014 ACR/ARHP Annual Meeting
Clinical Observation on Ankylosing Spondylitis Patients with Different Phenotypes
Background/Purpose :Juvenile and adult forms of ankylosing spondylitis (AS) have been shown different in initial symptoms,clinical presentation ,imaging manifestations and prognosis.So,according to the diagnostic criteria…Abstract Number: 614 • 2014 ACR/ARHP Annual Meeting
The Association of PPM1A with Inflammasome Activation in Ankylosing Spondylitis
The Association of PPM1A with Inflammasome Activation in Ankylosing SpondylitisBackground/Purpose Ankylosing spondylitis (AS) is a chronic inflammatory disorder usually affecting axial skeleton and joints. The…
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 62
- Next Page »